Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Epithelial Ovarian Cancer
56%
Ovarian Cancer
48%
Platinum Sensitivity
45%
BRCA mutation
45%
Overall Survival
36%
Pegylated Liposomal Doxorubicin
34%
Chemotherapy
32%
Advanced Ovarian Cancer
27%
Olaparib
27%
Rucaparib
27%
Progression-free Survival
27%
Phase II Study
24%
Carboplatin
24%
Ovarian Cancer Patients
23%
Retrospective Analysis
23%
Placebo
22%
Confidence Interval
22%
Phase II Trial
22%
Recurrent Ovarian Cancer
20%
Endometrial Cancer
19%
Monotherapy
19%
PARP Inhibitor (PARPi)
18%
Median Overall Survival
18%
BRCA Status
17%
Maintenance Therapy
17%
Paclitaxel
17%
Median Progression-free Survival
16%
Primary Peritoneal Cancer
16%
Serous Ovarian Cancer
15%
Randomized Phase III Trial
15%
BRCA mutation Carriers
15%
Maintenance Treatment
15%
Platinum Resistance
15%
Doxorubicin
14%
BRCA2 mutation
14%
BRCA1, BRCA2
14%
Health-related Quality of Life
13%
Platinum-based Chemotherapy
13%
Cytoreductive Surgery
13%
Partial Response
13%
Cisplatin
12%
Complete Response
12%
Disease Progression
11%
Response to Chemotherapy
11%
Weekly Topotecan
11%
Metastatic Breast Cancer
11%
Microsatellite Instability-high (MSI-H)
11%
Pembrolizumab
11%
Relapsed Ovarian Cancer
11%
Recurrent Endometrial Cancer
11%
Medicine and Dentistry
Ovarian Cancer
100%
Krukenberg Tumor
74%
Overall Survival
48%
Diseases
36%
Progression Free Survival
36%
BRCA Mutation
35%
Maintenance Therapy
29%
Breast Cancer
28%
BRCA1
25%
Malignant Neoplasm
25%
Placebo
24%
Olaparib
23%
Rucaparib
23%
Uterine Cancer
23%
Doxorubicin
23%
Quality of Life
19%
Monotherapy
18%
Recurrent Ovarian Cancer
17%
Carboplatin
16%
Female Genital Tract Cancer
15%
Recurrent Disease
14%
Homologous Recombination
14%
BRCA2
14%
Gemcitabine
13%
Topotecan
12%
Adverse Event
12%
Cervical Cancer
11%
BRCA Gene
11%
Pembrolizumab
11%
Health Care Cost
11%
Disease Exacerbation
11%
Paclitaxel
10%
Cost-Effectiveness Analysis
9%
Phase II Trials
9%
Cytoreductive Surgery
9%
Gamma Urogastrone
8%
PARP Inhibitor
8%
Phase III Trials
8%
Primary Peritoneal Carcinoma
8%
Genetic Screening
7%
Cardiotoxicity
7%
Metastatic Breast Cancer
7%
Positron Emission Tomography-Computed Tomography
7%
Letrozole
7%
Epidermal Growth Factor Receptor 2
7%
Microsatellite Instability
7%
DNA Mismatch Repair
7%
Adenocarcinoma
7%
Neoplasm
7%
Germ Cell
7%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Carcinoma
59%
Ovary Cancer
56%
Doxorubicin
37%
Overall Survival
34%
Chemotherapy
31%
Paclitaxel
26%
Progression Free Survival
24%
Carboplatin
21%
Breast Cancer
21%
Diseases
18%
Endometrium Cancer
15%
Pembrolizumab
15%
Malignant Neoplasm
15%
Placebo
15%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
14%
Cisplatin
12%
Gamma Urogastrone
12%
Recurrent Disease
12%
Topotecan
11%
Olaparib
11%
Cardiotoxicity
11%
Metastatic Breast Cancer
11%
Epidermal Growth Factor Receptor 2
11%
Phase II Trials
11%
Adverse Event
11%
Disease Exacerbation
10%
Peritoneum Cancer
9%
Tolerability
9%
Carcinoma
9%
Solid Malignant Neoplasm
9%
Hormone Receptor
9%
Monotherapy
9%
Anthracycline
8%
Rucaparib
7%
Liposome
7%
Letrozole
7%
Neoplasm
7%
Antitumor Activity
7%
Trastuzumab
5%
Docetaxel
5%
Neutropenia
5%
Neuropathy
5%
Phase III Trials
5%
Fulvestrant
5%
Endocrine Therapy
5%